High levels of CCL5 and CXCL10 in breast cancer correlate with advanced stages of the disease (Niwa et al., 2001; Ali and Lazennec, 2007; Soria and Ben-Baruch, 2008; Velasco-Velazquez et al., 2012) and reduced survival of metastatic breast cancer patients (Clark et al., 2021), respectively. Here, CXCL10 is linked to breast carcinoma.